Cardiac sarcoidosis and giant cell myocarditis after COVID‐19 infection

Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19. All patients received immunosuppressive therapy and improved gradually wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bollano, Entela, Polte, Christian Lars, Mäyränpää, Mikko I., Oldfors, Anders, Bergh, Niklas, Lehtonen, Jukka, Kandolin, Riina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539072/
https://www.ncbi.nlm.nih.gov/pubmed/35996829
http://dx.doi.org/10.1002/ehf2.14088
Descripción
Sumario:Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID‐19 infection might suggest that COVID‐19 could be a trigger for granulomatous myocarditis.

Ejemplares similares